Influence of polymorphisms in CYP2C9, VKORC1, MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-08-01 Epub Date: 2023-09-13 DOI:10.2217/pgs-2023-0099

Emílio Itamar de Freitas Campos, Karina Braga Gomes, Daniel Dias Ribeiro, Marja Kaarina Puurunen, Aline de Oliveira Magalhães Mourão, Isadora Gonçalves Ferreira, Manoel Otávio da Costa Rocha, Renan Pedra de Souza, Maria Auxiliadora Parreiras Martins

{"title":"Influence of polymorphisms in CYP2C9, VKORC1, MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients.","authors":"Emílio Itamar de Freitas Campos, Karina Braga Gomes, Daniel Dias Ribeiro, Marja Kaarina Puurunen, Aline de Oliveira Magalhães Mourão, Isadora Gonçalves Ferreira, Manoel Otávio da Costa Rocha, Renan Pedra de Souza, Maria Auxiliadora Parreiras Martins","doi":"10.2217/pgs-2023-0099","DOIUrl":null,"url":null,"abstract":"Background: Polymorphisms in the CYP2C9, VKORC1, MDR1 and APOE genes may impact warfarin dose. Aim: To investigate the influence of sociodemographic, clinical factors and polymorphisms *1, *2 and *3 for CYP2C9, -1639G>A for VKORC1, 3435C>T for MDR1, and ϵ2, ϵ3 and ϵ4 for APOE genes on the mean weekly warfarin maintenance dose in adults. Methods: This cross-sectional study recruited a calculated sample of 315 patients in three anticoagulation clinics in Brazil. A model containing the variables significantly associated with warfarin dose was estimated. Results: The mean age of patients was 64.1 ± 13.1 years, with 173 (54.9%) women. Age, use of amiodarone, genotype VKORC1 GA, genotype VKORC1 AA, genotypes CYP2C9*1/*2 or *1/*3 and genotypes CYP2C9*2/*2 or *2/*3 or *3/*3 were associated with a reduced warfarin dose. Conclusion: This study pointed out factors that could impact the management of oral anticoagulation.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"701-712"},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0099","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Polymorphisms in the CYP2C9, VKORC1, MDR1 and APOE genes may impact warfarin dose. Aim: To investigate the influence of sociodemographic, clinical factors and polymorphisms *1, *2 and *3 for CYP2C9, -1639G>A for VKORC1, 3435C>T for MDR1, and ϵ2, ϵ3 and ϵ4 for APOE genes on the mean weekly warfarin maintenance dose in adults. Methods: This cross-sectional study recruited a calculated sample of 315 patients in three anticoagulation clinics in Brazil. A model containing the variables significantly associated with warfarin dose was estimated. Results: The mean age of patients was 64.1 ± 13.1 years, with 173 (54.9%) women. Age, use of amiodarone, genotype VKORC1 GA, genotype VKORC1 AA, genotypes CYP2C9*1/*2 or *1/*3 and genotypes CYP2C9*2/*2 or *2/*3 or *3/*3 were associated with a reduced warfarin dose. Conclusion: This study pointed out factors that could impact the management of oral anticoagulation.

查看原文本刊更多论文

CYP2C9、VKORC1、MDR1和APOE基因多态性对巴西患者华法林维持剂量的影响。

背景：CYP2C9、VKORC1、MDR1和APOE基因多态性可能影响华法林剂量。目的：研究CYP2C9的社会人口学、临床因素和多态性*1、*2和*3，VKORC1的-1639G>A，MDR1的3435C>T，APOE基因的ε2、ε3和ε4对成人每周平均华法林维持剂量的影响。方法：这项横断面研究招募了来自巴西三家抗凝诊所的315名患者。估计了一个包含与华法林剂量显著相关的变量的模型。结果：患者平均年龄为64.1±13.1岁，女性173例（54.9%）。年龄、胺碘酮的使用、基因型VKORC1-GA、基因型VKORC1-AA、基因型CYP2C9*1/*2或*1/*3和基因型CYP2C9*2/*2、*2/*3或*3/*3与华法林剂量减少有关。结论：本研究指出了影响口服抗凝治疗的因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.